Combination Chemotherapy With or Without Autologous Stem Cell Transplant in Treating Patients With Central Nervous System B-Cell Lymphoma (NCT01511562)

🧪 Interventions in This Study

• carmustine (DRUG)
• cytarabine (DRUG)
• etoposide (DRUG)
• thiotepa (DRUG)
• G-CSF (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (126 Sites)

Showing the first 25 of 126 sites.

• Anchorage Associates in Radiation Medicine — Anchorage, Alaska
• Anchorage Radiation Therapy Center — Anchorage, Alaska
• Alaska Breast Care and Surgery LLC — Anchorage, Alaska
• Alaska Oncology and Hematology LLC — Anchorage, Alaska
• Alaska Women's Cancer Care — Anchorage, Alaska
• Anchorage Oncology Centre — Anchorage, Alaska
• Katmai Oncology Group — Anchorage, Alaska
• Providence Alaska Medical Center — Anchorage, Alaska
• Providence Saint Joseph Medical Center/Disney Family Cancer Center — Burbank, California
• UC San Diego Moores Cancer Center — La Jolla, California
• University of California Davis Comprehensive Cancer Center — Sacramento, California
• UCSF Medical Center-Mount Zion — San Francisco, California
• UCSF Medical Center-Parnassus — San Francisco, California
• Yale University — New Haven, Connecticut
• Moffitt Cancer Center — Tampa, Florida
• Emory University/Winship Cancer Institute — Atlanta, Georgia
• Saint Luke's Mountain States Tumor Institute — Boise, Idaho
• Saint Luke's Mountain States Tumor Institute - Fruitland — Fruitland, Idaho
• Saint Luke's Mountain States Tumor Institute - Meridian — Meridian, Idaho
• Saint Luke's Mountain States Tumor Institute - Nampa — Nampa, Idaho
• Saint Luke's Mountain States Tumor Institute-Twin Falls — Twin Falls, Idaho
• University of Illinois — Chicago, Illinois
• University of Chicago Comprehensive Cancer Center — Chicago, Illinois
• Reid Health — Richmond, Indiana
• University of Kansas Cancer Center — Kansas City, Kansas

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Lymphoma

• A Phase I Study of Bendamustine and Melphalan Conditioning and Autologous Stem Cell Transplantation for Treatment of Multiple Myeloma and Relapsed/Refractory B-cell Lymphoma in Elderly Patients — New York, New York
• A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma — La Jolla, California
• Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma — Calgary, Alberta
• Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma — Anchorage, Alaska
• A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant — New York, New York
• Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL — Chapel Hill, North Carolina

Explore by condition: All Lymphoma clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.